Eversense 365 Shows Strong Real-World Performance at ADA, Validating One-Year CGM System
Summary
Senseonics presented new real-world data for its Eversense 365 Continuous Glucose Monitoring (CGM) system at the American Diabetes Association (ADA) Scientific Sessions. The data demonstrated strong performance, sustained accuracy, and positive patient impact in both open and closed-loop systems, expanding on previous findings. This positive product validation follows recent financial improvements, including an 87% year-over-year revenue increase in Q1 2026 and the alleviation of going concern doubts. The strong real-world evidence is crucial for supporting the commercialization efforts and market adoption of Senseonics' differentiated one-year implantable CGM technology.
At the time of this announcement, SENS was trading at $6.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $348.2M. The 52-week trading range was $4.79 to $12.58. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.